“…UMEC + VI: 12.62 vs. 13.02, P = 0.022), leading to 17.39% and 21.47% lower mean annualized per-patient COPD-related ED costs (vs. other LAMA + LABAs: $289 vs. $368, P = 0.003; vs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: The results of CCK-8, Hoechst 33342/PI-staining, and flow cytometry showed that BA did not significantly promote cell proliferation (CCK-8: 0 μmol/L, 100%; 2.5 μmol/L, 98.58%; 5.0 μmol/L, 95.18%; 10.0 μmol/L, 98.11%; 50.0 μmol/L, 99.38%, F = 2.33, P > 0.05), but it did attenuate the effect of Dex on apoptosis (Hoechst 33342/PI-staining: Dex+ 50.0 μmol/L BA, 12.27% vs. Dex, 39.27%, t = 20.62; flow cytometry: Dex + 50.0 μmol/L BA, 12.68% vs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…However, the difference between sexes varied by age strata among persons without HIV: age under 40 years, 0.52 (95% CI, 0.13 to 0.92); ages 40 to 49 years, −0.07 (95% CI, −0.45 to 0.31); ages 50 to 59 years, 0.88 (95% CI, 0.62 to 1.14); ages 60 to 69 years, 1.39 (95% CI, 1.06 to 1.72); ages 70 years and older, 0.33 (95% CI, −0.53 to 1.19) (P for interaction = .001). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Survival analysis of postoperative immunotherapy responses by BRAF status revealed that BRAF wildtype lesions were associated with a response to checkpoint inhibition (median OS: with immunotherapy, undefined; without immunotherapy, 13.0 months [range, 1.1-61.7 months]; P = .001; log-rank test) while BRAF variant lesions (median OS: with immunotherapy, 9.8 months [range, 2.9-39.8 months]; without immunotherapy, 9.5 months [range, 2.5-67.2 months]; P = .81; log-rank test) were not. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…FSA was associated with a reduction in AREs of 55% (10.9%-4.9%; P less than0.001), and BSA with a reduction in AREs of 39% (13.3%-8.1%; P less than0.001). FSA compared with BSA was associated with a greater reduction in SABA use (-0.66 canister equivalents over 6 months, P less than0.001) and a lower likelihood of filling an oral steroid prescription, 35.8% of FSA patients compared with 38.0% of BSA patients (OR, 0.801; 95% CI, 0.662-0.970; P=0.023). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…GI-related costs ($4,456) comprised 39.8% of total all-cause costs, while IBS-C-related costs ($1,335) accounted for 11.9% and were primarily driven by costs of other outpatient services (50.3%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Patients with a positive screen for bipolar disorder on the MDQ were more likely than patients who screened MDQ-negative to report severe depression-related impairment (scores of 7 and higher on the SDS scale) with work life (54.5% vs. 24.1%, respectively, P = 0.002), social life (66.7% vs. 39.2%, P = 0.008), and family life (66.7% vs. 34.2%, P = 0.002) on the SDS. …”
Enlace del recurso
Enlace del recurso

“…Subanalysis of patients on a lipid-lowering agent found that a significantly higher proportion (85.2%) in the LC group were at goal total cholesterol compared with 60.7% for UC (P=0.012) and at goal LDL-C (66.7% for LC vs. 39.3% for UC, P=0.016). However, a lower proportion were at goal HDL-C for LC (21.3%) versus 42.9% for UC (P=0.043). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Further, weight loss is significantly associated with HbA1c less than  7.0% (MARS-5: OR = 3.60, 95% CI = 2.39-5.46; mMPR: OR 2.99, 95% CI = 1.45-6.17). CONCLUSIONS: This study has provided additional evidence in a managed, integrated setting that in patients treated for T2DM, weight loss is associated with good glycemic control. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Differences in visit-related labor costs (QW: $8.34, QM: $3.43; P=0.108) and injection supply costs (QW: $4.39, QM: $1.67; P less than0.001) accounted for the largest portions of the total monthly cost differential between the treatment regimens. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Only 53.7% had at least 1 OAB diagnosis recorded during the 18-month eligibility period. 44.5% of patients did not have a refill after the initial (index) pharmacy claim (39.4% for oxy-ER, 42.7% for tol-ER, 46.1% for tol-IR, and 59.3% for oxy-IR; P = 0.004). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the first-line cohort, ELPT at 30, 60, and 90 days was 98.39%, 70.97%, and 56.45%, respectively; the mean (± SD) number of days to discontinuation was 112.2 (± 62.8); the mean (± SD) PDC was 84.7% (± 16.7%); and the mean (± SD) MPR was 85.2% (± 16.9%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Entecavir was superior to lamivudine in the proportion of subjects who achieved undetectable HBV DNA (less than 300 copies per mL) by polymerase- chain reaction assay at week 48 (69.1% vs. 39.8%, respectively) (P less than 0.001). In the REVEAL-HBV study after statistical adjustment for age, gender, cigarette smoking, and alcohol consumption, rates of CC, DC, and HCC were associated with higher HBV DNA levels (e.g., compared with the reference category [less than 300 copies per mL], adjusted hazard ratios for HCC were 1.2, 2.9, 9.5, and 15.2 for serum HBV DNA levels of 300-9,999, 10,000-99,999, 100,000-999,999, and e 1 million copies per mL, respectively). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The incidence of catheter-related complications in the observation group (8.3%, 6/72) was lower than that of the control group (54.2%, 39/72) and the difference was statistically significant (P<0.01). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Subgroup analysis based on MMR status revealed DCR of 54.0% (95% CI: 47.0–62.0%; p = 0.83) for the dMMR group, and 31.0% (95% CI: 25.0–39.0%; p = 0.14) for the pMMR group. The efficacy of PD-1/PD-L1 inhibitors was significantly higher in the dMMR group compared to the pMMR group, in terms of both ORR (OR = 6.30; 95% CI = 3.60–11.03; p < 0.05) and DCR (OR = 2.57; 95% CI = 1.66–3.99; p < 0.05). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Mexican American individuals living in more disadvantaged areas had worse performance than those living in ADI quintile 1 on 7 of 11 cognitive tests, including SEVLT Learning (ADI quintile 5: β = −2.50; 95% CI, −4.46 to –0.54), SEVLT Delayed Recall (eg, ADI quintile 3: β = −1.11; 95% CI, −1.97 to –0.24), WMS-III Digit Span Forward (eg, ADI quintile 4: β = −1.14; 95% CI, −1.60 to –0.67), TMT part A (ADI quintile 5: β = 7.85; 95% CI, 1.28-14.42), TMT part B (eg, ADI quintile 5: β = 31.5; 95% CI, 12.16-51.35), Letter Fluency (ADI quintile 4: β = −2.91; 95% CI, −5.39 to −0.43), and DSST (eg, ADI quintile 5: β = −4.45; 95% CI, −6.77 to –2.14). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Preteens born ≥ 4 kg had lower median (IQR) C3 concentrations (1.38 (1.22, 1.52) g/L vs. 1.4 (1.26, 1.6) g/L, p = 0.043) and lower median (IQR) ICAM-1 concentrations (345.39 (290.34, 394.91) ng/mL vs. 387.44 (312.91, 441.83) ng/mL, p = 0.040), than those born < 4 kg. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A total of 203 Omicron PCR-positive respiratory swabs (53 BA.1, 48 BA.2, 23 BQ.1, 39 XBB.1.5 and 40 other subvariants) from the period February to March 2022 and from March 2023 were examined. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Of the 359 eligible EXCEL participants, 205 (57.1%) consented, 199 (55.4%; intervention: 106/199, 53.3%; control: 93/199, 46.7%) started the study, and 183 (51%; intervention: 100/183, 54.6%; control: 83/183, 45.4%) and 141 (39.3%; intervention: 69/141, 48.9%; control: 72/141, 51.1%) completed 12- and 24-week measures, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Among those who reported abstinence, 90% (35/39) of Pivot participants and 90% (26/29) of QuitGuide participants indicated that their cessation program helped them quit. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso